|
|
|
| Jun. 26, 2008 |
New Data Show Preemptive Treatment May Significantly Reduce Skin Toxicities in Patients Receiving Vectibix(R) (Panitumumab)
|
| Jun. 18, 2008 |
Amgen and Wyeth Statement on Outcome of Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) Meeting
|
| Jun. 18, 2008 |
Enbrel(R) (etanercept) Application for the Treatment of Pediatric Psoriasis to be Discussed at FDA Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) Meeting
|
| Jun. 15, 2008 |
Romiplostim Data Show Potential Long-Term Efficacy and Safety in Adults with Chronic ITP
|
| Jun. 9, 2008 |
Amgen SVP of North American Commercial Operations James Daly to Present at the Goldman Sachs Healthcare Conference
|
| Jun. 6, 2008 |
Amgen Names Anna Richo Senior Vice President of Worldwide Compliance
|
| Jun. 5, 2008 |
2008 Recipients of Amgen Award for Science Teaching Excellence Announced
|
| Jun. 4, 2008 |
Amgen and Wyeth Statement on the FDA Early Communication About Tumor Necrosis Factor (TNF) Blockers
|
| Jun. 1, 2008 |
Updated Data from Ongoing Phase 3 Trials Support the Continued Study of Vectibix(R) (panitumumab) in Combination with Standard Chemotherapy
|
| May. 31, 2008 |
Interim Phase 2 Results of Open-Label Clinical Trial of Denosumab in Giant Cell Tumor of Bone Demonstrated 87 Percent Response Rate
|
| May. 31, 2008 |
Amgen Presents New Data at ASCO on Four Investigational Molecules from Oncology Pipeline
|
| May. 31, 2008 |
Amgen Reports Positive Data at ASCO from Three Studies of Denosumab in Cancer Patients
|
| May. 29, 2008 |
Amgen to Webcast Investor Meeting at Upcoming American Society of Clinical Oncology Conference
|
| May. 28, 2008 |
Denosumab Achieved Superior Bone Mineral Density Gains in Head-to-Head Trial Versus Weekly Alendronate (FOSAMAX(R))
|
| May. 27, 2008 |
Amgen Announces Webcast to Discuss Results of denosumab Phase 3 Head-to-Head Study versus alendronate at the Upcoming European Symposium on Calcified Tissues Conference
|
| May. 22, 2008 |
Amgen Posts Medical Education and Foundation Grants and Donations as Part of the Company's 'Clearly Amgen' Initiative
|
| May. 19, 2008 |
Denosumab Osteoporosis Study Meets Primary and All Secondary Bone Mineral Density Endpoints in Alendronate (FOSAMAX(R)) Transition Study
|
| May. 15, 2008 |
Amgen Highlights Data to Be Presented at ASCO
|
| May. 13, 2008 |
Amgen VP of Investor Relations Arvind Sood to Present at the Baird Growth Stock Conference
|
| May. 7, 2008 |
Amgen Announces Voting Results of Annual Meeting of Stockholders
|
| May. 6, 2008 |
Amgen to Participate in CHMP Oncology Scientific Advisory Group Meeting in May
|
| May. 1, 2008 |
Amgen to Participate in Dermatologic and Ophthalmic Drugs Advisory Committee Meeting in June
|
| Apr. 30, 2008 |
Amgen CFO Bob Bradway to Present at the Morgan Stanley Global Healthcare Unplugged Conference
|
| Apr. 24, 2008 |
Amgen's First Quarter 2008 Adjusted Earnings Per Share Increased 4 percent to $1.12
|
| Apr. 16, 2008 |
Amgen Announces Webcast of 2008 First Quarter Financial Results
|
| Apr. 15, 2008 |
Amgen Presents Preclinical and Clinical Data from Oncology Programs
|
| Apr. 14, 2008 |
Amgen Scientist Visits Los Angeles Classroom During Teach For America Week
|
| Apr. 13, 2008 |
Early Data on Amgen's Anti-Angiogenesis Pipeline Molecules Suggest Biologic Activity Across Tumor Types
|
| Apr. 11, 2008 |
Amgen-Teach for America Summit to Focus on Strategies for Advancing Math and Science Education
|
| Apr. 8, 2008 |
Amgen Statement on Romiplostim PDUFA Date
|
| Apr. 3, 2008 |
Amgen's Oncology Pipeline Data Highlighted at Upcoming Scientific Meeting
|
| Apr. 3, 2008 |
National Kidney Foundation Introduces Plan to Track Patients in National Screening Program
|
| Apr. 2, 2008 |
Pivotal Phase 3 Data Show Denosumab Increased Bone Density at Multiple Skeletal Sites in Early and Later Stage Postmenopausal Women
|
| Mar. 17, 2008 |
Amgen and Wyeth Announce Updates to U.S. Prescribing Information for Enbrel(R)
|
| Mar. 14, 2008 |
Amgen to Present at the 28th Annual Cowen Healthcare Conference and the 11th Annual Lehman Brothers Global Healthcare Conference
|
| Mar. 13, 2008 |
Amgen to Discuss Benefits and Risks of ESA Treatment for Cancer Patients with Anemia Due to Chemotherapy at FDA ODAC Meeting
|
| Mar. 12, 2008 |
Amgen Statement on Successful Outcome of Romiplostim Panel Meeting
|
| Mar. 12, 2008 |
Amgen to Discuss Romiplostim Application at FDA ODAC Meeting
|
| Mar. 7, 2008 |
Amgen Announces Update to U.S. Prescribing Information for Aranesp(R) and EPOGEN(R)
|
| Mar. 5, 2008 |
Kyowa Hakko and Amgen Enter Licensing Agreement for Anti-CCR4 Humanized Monoclonal Antibody
|
| Mar. 5, 2008 |
The Colon Cancer Alliance Teams up with Joan Lunden for Amgen Sponsored Workshop Series Designed to Provide Support to Patients and Caregivers
|
| Mar. 5, 2008 |
EU Commission Approves Updated Prescribing Information for Aranesp(R)
|
| Mar. 4, 2008 |
KRAS Biomarker Analysis from Pivotal Vectibix(TM) Trial Published
|
| Feb. 4, 2008 |
Amgen and Takeda Announce Exclusive Collaboration in Japan on up to 13 Amgen Clinical Candidates
|
| Feb. 1, 2008 |
New Findings Show Enbrel(R) (etanercept) Significantly Reduced Levels of C-Reactive Protein, a Marker of Inflammation, in Patients with Moderate to Severe Plaque Psoriasis
|
| Jan. 31, 2008 |
Pooled Phase 3 Study of Nplate(TM) (Romiplostim) in Adult Patients with Chronic ITP Published in The Lancet
|
| Jan. 28, 2008 |
Amgen Statement on Aranesp Manuscript in the Journal of Clinical Oncology
|
| Jan. 27, 2008 |
Interim Safety Data Presented on Vectibix(TM) (Panitumumab) in Combination with Standard Chemotherapy
|
| Jan. 24, 2008 |
Denosumab Osteoporosis Study Met Primary and All Secondary Bone Mineral Density Endpoints in a Head-to-Head Comparison with Weekly Alendronate (FOSAMAX(R))
|
| Jan. 24, 2008 |
Amgen's Fourth Quarter 2007 Adjusted Earnings Per Share (EPS) Increased 11 Percent to $1.00; Full Year 2007 Adjusted EPS Increased 10 Percent to $4.29
|
| Jan. 24, 2008 |
KRAS Gene Status May Impact Vectibix(TM) (Panitumumab) Efficacy and Patient Reported Outcomes in Advanced Colorectal Cancer Patients
|
| Jan. 17, 2008 |
Amgen Commences Registered Exchange Offer for Its Senior Floating Rate Notes Due 2008, 5.85 Percent Senior Notes Due 2017 and 6.375 Percent Senior Notes Due 2037
|
| Jan. 16, 2008 |
New Study Reports Enbrel(R) (Etanercept) Significantly Improved Moderate to Severe Plaque Psoriasis in Children and Adolescents
|
| Jan. 16, 2008 |
Amgen Announces Webcast of 2007 Fourth Quarter and Full Year Financial Results
|
| Jan. 10, 2008 |
Breakaway from Cancer Public Service Announcement Spreads Support and Hope
|
| Jan. 8, 2008 |
Amgen Updates 2007 Adjusted EPS Guidance and Outlines 2008 Expense Outlook at the JP Morgan Healthcare Conference
|
| Jan. 4, 2008 |
Amgen to Present at the 26th Annual JP Morgan Healthcare Conference
|
